IL235781A0 - Methods for preparing fully human bispecific antibodies using a common light chain - Google Patents
Methods for preparing fully human bispecific antibodies using a common light chainInfo
- Publication number
- IL235781A0 IL235781A0 IL235781A IL23578114A IL235781A0 IL 235781 A0 IL235781 A0 IL 235781A0 IL 235781 A IL235781 A IL 235781A IL 23578114 A IL23578114 A IL 23578114A IL 235781 A0 IL235781 A0 IL 235781A0
- Authority
- IL
- Israel
- Prior art keywords
- methods
- light chain
- bispecific antibodies
- fully human
- common light
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/488,628 US20130045492A1 (en) | 2010-02-08 | 2012-06-05 | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
PCT/US2013/044257 WO2013184761A1 (en) | 2012-06-05 | 2013-06-05 | Methods for making fully human bispecific antibodies using a common light chain |
Publications (1)
Publication Number | Publication Date |
---|---|
IL235781A0 true IL235781A0 (en) | 2015-01-29 |
Family
ID=48652344
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL235781A IL235781A0 (en) | 2012-06-05 | 2014-11-18 | Methods for preparing fully human bispecific antibodies using a common light chain |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP2854523A1 (da) |
JP (1) | JP2015525071A (da) |
KR (1) | KR20150023535A (da) |
CN (1) | CN104582476B (da) |
AU (1) | AU2013271737A1 (da) |
CA (1) | CA2874846A1 (da) |
HK (1) | HK1208994A1 (da) |
IL (1) | IL235781A0 (da) |
MX (1) | MX2014014891A (da) |
RU (1) | RU2014153674A (da) |
SG (2) | SG11201407644UA (da) |
WO (1) | WO2013184761A1 (da) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
US20120021409A1 (en) | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
RU2724663C2 (ru) | 2010-02-08 | 2020-06-25 | Ридженерон Фармасьютикалз, Инк. | Мышь с общей легкой цепью |
US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
US20140013456A1 (en) | 2012-03-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
SI2883449T1 (en) | 2012-03-16 | 2018-05-31 | Regeneron Pharmaceuticals, Inc. | Light-chain modified antibodies with histidine and genetically modified rodents for their production |
EP2825035A1 (en) | 2012-03-16 | 2015-01-21 | Regeneron Pharmaceuticals, Inc. | Mice that produce antigen-binding proteins with ph-dependent binding characteristics |
CA2865645A1 (en) | 2012-03-16 | 2013-09-19 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing immunoglobulin sequences ph-sensitive for antigen building |
EP3594232A1 (en) | 2012-04-20 | 2020-01-15 | Merus N.V. | Methods and means for the production of ig-like molecules |
TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
EP2970437A1 (en) * | 2013-03-13 | 2016-01-20 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
KR102614189B1 (ko) | 2014-11-17 | 2023-12-18 | 리제너론 파아마슈티컬스, 인크. | Cd3xcd20 이특이적 항체를 이용한 종양의 치료 방법 |
EP3023437A1 (en) | 2014-11-20 | 2016-05-25 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
LT3221357T (lt) * | 2014-11-20 | 2020-08-25 | F. Hoffmann-La Roche Ag | Bendros lengvosios grandinės ir naudojimo būdai |
CA2981312C (en) | 2015-03-30 | 2023-09-26 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
AU2016261854B2 (en) | 2015-05-12 | 2022-05-26 | Regeneron Pharmaceuticals, Inc. | Multimeric protein purity determination |
MD3353212T2 (ro) * | 2015-09-23 | 2022-03-31 | Regeneron Pharma | Anticorpi bispecifici anti-CD3 optimizați și utilizările acestora |
CA3011359A1 (en) | 2016-01-13 | 2017-07-20 | Regeneron Pharmaceuticals, Inc. | Rodents having an engineered heavy chain diversity region |
MX2020013652A (es) | 2018-06-14 | 2022-04-21 | Regeneron Pharma | Animales no humanos con capacidad de reordenamiento dh-dh en las secuencias codificantes de la cadena pesada de inmunoglobulina. |
AU2019331024A1 (en) | 2018-08-31 | 2021-03-18 | Regeneron Pharmaceuticals, Inc. | Dosing strategy that mitigates cytokine release syndrome for CD3/C20 bispecific antibodies |
SG11202107589PA (en) | 2019-02-22 | 2021-08-30 | Regeneron Pharma | Rodents having genetically modified sodium channels and methods of use thereof |
KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
TW202229328A (zh) | 2020-09-11 | 2022-08-01 | 美商再生元醫藥公司 | 抗原特異性抗體之鑑定及產生 |
AU2021400584A1 (en) | 2020-12-16 | 2023-06-29 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized fc alpha receptors |
MX2023007401A (es) | 2020-12-23 | 2023-07-06 | Regeneron Pharma | Acidos nucleicos que codifican anticuerpos modificados por anclaje y usos de los mismos. |
EP4267608A1 (en) | 2020-12-23 | 2023-11-01 | Regeneron Pharmaceuticals, Inc. | Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1341351C (en) * | 1988-09-06 | 2002-03-26 | Marc D. Better | Production of chimeric mouse-human antibodies with specificity to human tumor antigens |
US5770429A (en) * | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
JPH08509612A (ja) * | 1993-04-26 | 1996-10-15 | ジェンファーム インターナショナル インコーポレイテッド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
US6596541B2 (en) * | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US6881557B2 (en) * | 2001-07-12 | 2005-04-19 | Arrowsmith Technologies Llp | Super humanized antibodies |
DE50115580D1 (de) * | 2001-10-01 | 2010-09-16 | Deutsches Krebsforsch | Verfahren zur Herstellung von Protein-Bibliotheken und zur Selektion von Proteinen daraus |
AU2003214842A1 (en) * | 2002-01-17 | 2003-09-02 | Albert Einstein College Of Medicine Of Yeshiva University | Mutations caused by activation-induced cytidine deaminase |
JP5139626B2 (ja) * | 2002-06-14 | 2013-02-06 | イミューノメディクス、インコーポレイテッド | モノクローナル抗体hPAM4 |
CN101962408A (zh) * | 2002-07-12 | 2011-02-02 | 杰斐逊·富特 | 超人源化抗体 |
EP3456190B1 (en) * | 2008-06-27 | 2021-11-24 | Merus N.V. | Antibody producing transgenic murine animal |
RU2724663C2 (ru) * | 2010-02-08 | 2020-06-25 | Ридженерон Фармасьютикалз, Инк. | Мышь с общей легкой цепью |
SI2739740T1 (sl) * | 2011-08-05 | 2019-12-31 | Regeneron Pharmaceuticals, Inc. | Humanizirane univerzalne lahkoverižne miši |
-
2013
- 2013-06-05 EP EP13729875.8A patent/EP2854523A1/en not_active Ceased
- 2013-06-05 KR KR20147036869A patent/KR20150023535A/ko not_active Application Discontinuation
- 2013-06-05 CA CA2874846A patent/CA2874846A1/en not_active Abandoned
- 2013-06-05 AU AU2013271737A patent/AU2013271737A1/en not_active Abandoned
- 2013-06-05 JP JP2015516160A patent/JP2015525071A/ja active Pending
- 2013-06-05 CN CN201380030014.1A patent/CN104582476B/zh active Active
- 2013-06-05 SG SG11201407644UA patent/SG11201407644UA/en unknown
- 2013-06-05 MX MX2014014891A patent/MX2014014891A/es unknown
- 2013-06-05 SG SG10201609535TA patent/SG10201609535TA/en unknown
- 2013-06-05 RU RU2014153674A patent/RU2014153674A/ru not_active Application Discontinuation
- 2013-06-05 WO PCT/US2013/044257 patent/WO2013184761A1/en active Application Filing
-
2014
- 2014-11-18 IL IL235781A patent/IL235781A0/en unknown
-
2015
- 2015-10-06 HK HK15109745.2A patent/HK1208994A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
SG10201609535TA (en) | 2017-01-27 |
KR20150023535A (ko) | 2015-03-05 |
WO2013184761A1 (en) | 2013-12-12 |
CN104582476B (zh) | 2017-03-08 |
SG11201407644UA (en) | 2014-12-30 |
EP2854523A1 (en) | 2015-04-08 |
HK1208994A1 (en) | 2016-03-24 |
CN104582476A (zh) | 2015-04-29 |
AU2013271737A1 (en) | 2015-01-22 |
JP2015525071A (ja) | 2015-09-03 |
RU2014153674A (ru) | 2016-07-27 |
MX2014014891A (es) | 2015-06-17 |
CA2874846A1 (en) | 2013-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1208994A1 (en) | Methods for making fully human bispecific antibodies using a common light chain | |
HUS2200016I1 (hu) | Bispecifikus EGFR/C-MET-ellenanyagok | |
IL266268B (en) | Mice with humanized light chain | |
HK1202560A1 (en) | Light chain-bridged bispecific antibody | |
IL222197A0 (en) | CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY | |
EP2922874A4 (en) | BISPECIFIC ANTIBODIES | |
ZA201407272B (en) | Anti-baff-anti-il-17 bispecific antibodies | |
HK1205145A1 (en) | Improved antibody light chains |